A nurse is preparing to administer enoxaparin 0.75 mg/kg subcutaneously to a client who weighs 154 lb. The amount available is enoxaparin 60 mg/0.6 mL. How many mL should the nurse administer?(Round the answer to the nearest tenth. Use a leading zero if it applies. Do not use a trailing zero.).

Choice A rationale:
Allergy to eggs is not a contraindication for taking chondroitin with glucosamine. These supplements do not contain eggs and are generally safe for individuals with egg allergies.
Choice B rationale:
Hypotension is not directly related to the use of chondroitin with glucosamine. These supplements are not known to cause significant changes in blood pressure.
Choice C rationale:
History of hypoglycemia is not a specific concern with chondroitin and glucosamine supplements. These supplements do not significantly impact blood sugar levels in people without diabetes.
Choice D rationale:
The correct choice. The nurse should instruct the client to use chondroitin with glucosamine with caution if they are on anticoagulant therapy. Chondroitin and glucosamine may have mild anticoagulant effects, and when combined with prescribed anticoagulant medications, there is a potential risk of increased bleeding or altered blood clotting times. It is essential to monitor the client's coagulation parameters closely if they decide to use these supplements.

Choice A rationale:

A PT (Prothrombin Time) of 12 seconds is not indicative of the effectiveness of heparin therapy for a pulmonary embolism. PT measures the extrinsic pathway of the coagulation cascade, and it is more relevant to monitor in patients on warfarin therapy.

Choice B rationale:

The aPTT (Activated Partial Thromboplastin Time) of 75 seconds is the correct choice as it reflects the effectiveness of unfractionated heparin therapy. Heparin works by inhibiting clotting factors in the intrinsic pathway, and the aPTT is used to monitor heparin's anticoagulant effect. The normal range for aPTT is typically 25-35 seconds.

Choice C rationale:

An INR (International Normalized Ratio) of 1.1 is not the appropriate parameter to assess the effectiveness of heparin therapy. INR is primarily used to monitor the effectiveness of oral anticoagulants like warfarin, not heparin.

Choice D rationale:

The platelet count of 200,000/mm² is not a suitable parameter to evaluate the effectiveness of heparin therapy. Platelet count is important for assessing the risk of bleeding or clotting disorders but does not directly measure the impact of heparin on clotting factors.